CCFA Conference Notes 2016 (part 2) -Pediatric Lecture

This blog entry has abbreviated/summarized this terrific presentation; most of the material has been covered in this blog in prior entries but still this was a useful review. Though not intentional, some important material is likely to have been omitted; in addition, transcription errors are possible as well.

2nd Lecture: What is Next in Treatments for Pediatric Patients? –Dr. Michael Rosen

I really enjoyed meeting Dr. Rosen. He is super-friendly and knowledgeable.

Combination therapy. Grossi V et al showed improvement in infliximab durability with concomitant therapy.

Screen Shot 2016-04-17 at 11.44.52 AM Screen Shot 2016-04-17 at 11.44.38 AM

Screen Shot 2016-04-17 at 11.46.30 AM

Now starting COMBINE trial (ImproveCareNow)–randomized to low dose MTX or placebo in combination with anti-TNF agent.

Screen Shot 2016-04-17 at 11.42.32 AM

Therapeutic drug monitoring in pediatrics. Is this an alternative to combination therapy? Rationale (see slide): lower antibody formation if trough levels maintained. IFX level >5.5 associated with persistent remission (Singh et al 2014). Children are growing and they may need more adjustments. In Cincy, checking levels at week 14 after initiation and then every 6-12 months.

Screen Shot 2016-04-17 at 11.48.03 AM Screen Shot 2016-04-17 at 11.47.12 AM

Acute Severe Ulcerative Colitis. High rates of dose escalation in this population. Some of this is due to more rapid clearance of anti-TNF –leaking in gut and other mechanisms as well. Week 8 level of 40 associated with clinical response. Thus, this population may benefit from 10 mg/kg at start (in those with albumin <3) and may need more frequent dosing, especially early into treatment (?0, 2, 6, 10). ARCH study to look into this further

Screen Shot 2016-04-17 at 11.49.33 AM

Screen Shot 2016-04-17 at 11.49.45 AM

Vedolizumab. Conrad MA 2015. About 1/3rd of these refractory patients in this abstract responded.

Screen Shot 2016-04-17 at 11.50.01 AM

Screen Shot 2016-04-17 at 11.50.16 AM

Ustekinumab . IL-12 & IL-23 blockage. No studies in pediatrics. Case report reviewed of good response in a refractory case.

Enteral therapy. Specific carbohydrate diet experience. These diets have some published data, most retrospective studies. Our group (Cohen SA et al) did perform a small prospective study. Sigall-Boneh R et al showed improvement with partial enteral nutrition.

Screen Shot 2016-04-17 at 11.53.14 AM

Screen Shot 2016-04-17 at 11.53.26 AM

 

Screen Shot 2016-04-17 at 11.54.44 AM

Screen Shot 2016-04-17 at 11.55.08 AM Screen Shot 2016-04-17 at 11.54.57 AM

Very early-onset of IBD. IL-10 receptor deficiency was a key early discovery and can be treated with stem cell transplant. STAT3 mutation case reviewed which was managed with tocilizumab. More targeted therapy expected based on specific mutations.

Screen Shot 2016-04-17 at 11.55.33 AM

 

Advertisements

One thought on “CCFA Conference Notes 2016 (part 2) -Pediatric Lecture

  1. Pingback: Top Posts 2016 | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s